Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S provides an update on its ongoing share repurchase activity conducted under EU Market Abuse Regulation safe harbour rules. As part of an overall programme to repurchase up to DKK 15 billion of B shares during the 12-month period beginning 4 February 2026, the company initiated a specific programme on 6 May 2026 to buy back B shares for up to DKK 11,200,000,010.45 through 1 February 2027. Including purchases from 6–10 July 2026, a total of 9,225,000 B shares have been repurchased under this programme for DKK 2,734,545,468. Novo Nordisk now holds 41,169,480 B shares as treasury shares, equal to 0.9% of the share capital, out of total A and B shares of 4,465,000,000. Since 4 February 2026, the company has repurchased 23,984,179 B shares at an average price of DKK 272.45 per share, corresponding to a total transaction value of DKK 6,534,545,458.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme conducted under EU Safe Harbour Rules. The company is running a 12‑month buyback of up to DKK 15 billion that began on 4 February 2026, including a sub‑programme started on 6 May 2026 to repurchase B shares for up to DKK 11,200,000,010.45.
As of 3 July 2026, Novo Nordisk has repurchased a total of 23,009,179 B shares at an average price of DKK 270.32 per share, for a transaction value of DKK 6,219,775,971. Following recent purchases, the company holds 40,194,480 B shares as treasury shares, equal to 0.9% of its share capital, out of a total of 4,465,000,000 A and B shares outstanding including treasury shares.
Novo Nordisk A/S provides an update on its B share repurchase programme. The company plans to repurchase up to DKK 15 billion of B shares over 12 months beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 from 6 May 2026 to 1 February 2027.
As of 26 June 2026, Novo Nordisk has repurchased 22,009,179 B shares since 4 February 2026 at an average price of DKK 268.02 per share, for a total of DKK 5,898,848,910. Under the sub-programme initiated 6 May 2026, 7,250,000 B shares have been repurchased for DKK 2,098,848,921.
Following these transactions, Novo Nordisk holds 39,194,480 B shares of DKK 0.10 as treasury shares, equal to 0.9% of its share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over a 12-month period beginning 4 February 2026, the company is running a specific programme initiated on 6 May 2026 to repurchase up to DKK 11,200,000,010.45 of B shares through 1 February 2027.
Including transactions from 15–19 June 2026, the company has accumulated 6,200,000 B shares under this programme with a total transaction value of DKK 1,777,005,178. As of 19 June 2026, Novo Nordisk has repurchased 20,959,179 B shares since 4 February 2026 at an average price of DKK 266.09, equal to DKK 5,577,005,168. The company now holds 38,144,480 B shares as treasury shares, representing 0.9% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to repurchase B shares for up to DKK 15 billion over a 12-month period beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.
As of 12 June 2026, Novo Nordisk has repurchased 19,884,179 B shares at an average price of DKK 264.99 per share, for a total of DKK 5,269,055,819. The company now holds 37,069,480 B shares as treasury shares, representing 0.8% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S provides an update on its ongoing share repurchase activity. The company is running a broader share buyback programme of up to DKK 15 billion over a 12-month period beginning 4 February 2026, including a specific programme initiated 6 May 2026 to repurchase B shares for up to DKK 11,200,000,010.45 through 1 February 2027.
As of the latest update, accumulated purchases under the May 2026 programme total 4,000,000 B shares with a transaction value of DKK 1,158,452,492. Novo Nordisk now holds 35,944,480 B shares of DKK 0.10 as treasury shares, equal to 0.8% of its 4,465,000,000 A and B shares outstanding.
Since 4 February 2026, the company has repurchased 18,759,179 B shares at an average price of DKK 264.32 per share, for a total of DKK 4,958,452,482 under the 12‑month programme. The repurchases are conducted under EU Safe Harbour Rules, and detailed daily transaction data is made available on novonordisk.com.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running a broader plan to buy back up to DKK 15 billion of B shares over 12 months beginning 4 February 2026. Within this, a specific programme started on 6 May 2026 allows repurchases of B shares up to DKK 11,200,000,010.45 through 1 February 2027.
Since the 26 May 2026 update, Novo Nordisk repurchased several B-share blocks, bringing accumulated repurchases under the current programme to 3,130,000 B shares with a total transaction value of DKK 913,270,696. As of 29 May 2026, since 4 February 2026 the company has bought back 17,889,179 B shares at an average price of DKK 263.47, for DKK 4,713,270,686 in total. Novo Nordisk now holds 35,074,480 B shares as treasury shares, equal to 0.8% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over the 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.
From 18–22 May 2026, Novo Nordisk repurchased B shares each day in blocks of 210,000 shares, bringing total purchases under the current programme to 2,289,849 B shares with a transaction value of DKK 670,560,306. As of 22 May 2026, the company has repurchased 17,049,028 B shares since 4 February 2026 at an average price of DKK 262.22, for a total of DKK 4,470,560,295.
Following these transactions, Novo Nordisk holds 34,234,329 B shares as treasury shares, equal to 0.8% of its share capital. Total A and B shares outstanding, including treasury shares, are 4,465,000,000.
Novo Nordisk reports that the EU’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation of a once-weekly Wegovy 7.2 mg single-dose pen for people living with obesity. Wegovy 7.2 mg is already available in the EU as three 2.4 mg injections.
The decision is supported by phase 3 STEP UP trials, where injectable semaglutide 7.2 mg produced a 20.7% mean weight loss in adults with obesity and 14.1% mean weight loss in adults with obesity and type 2 diabetes. In STEP UP, 31.2% of patients achieved at least 25% weight loss, and in STEP UP T2D, 21.3% achieved at least 20% weight loss.
The 7.2 mg single-dose pen is already approved in the US and UK, and Novo Nordisk expects to launch it in the EU in Q3 2026, adding a more convenient administration option to its existing obesity portfolio.
Novo Nordisk reports that the EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending EU marketing authorisation for Wegovy® pill, a once-daily 25 mg oral semaglutide, for reducing excess body weight and maintaining long-term weight reduction in adults.
The opinion also supports including SELECT cardiovascular outcomes data in the label, showing Wegovy reduces the risk of major adverse cardiovascular events such as cardiovascular death, heart attack and stroke. In the phase 3b OASIS 4 trial, adherent patients achieved 16.6% mean weight loss, with about one in three reaching at least 20% weight loss.
The safety and tolerability profile matched previous semaglutide weight management trials, and semaglutide is backed by more than 50 million patient-years of real-world safety data. Novo Nordisk notes strong early U.S. demand for Wegovy pill and expects to bring the oral treatment to its first markets outside the U.S. in the second half of 2026, pending approvals.